HomeNBY • NYSEAMERICAN
add
NovaBay Pharmaceuticals Inc
Previous close
$1.14
Day range
$1.01 - $1.14
Year range
$0.46 - $4.44
Market cap
6.25M USD
Avg Volume
1.39M
P/E ratio
6.49
Dividend yield
-
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 1.89M | 16.94% |
Net income | -1.92M | -21.26% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -1.89M | -17.32% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 5.34M | 611.58% |
Total assets | 6.91M | 76.08% |
Total liabilities | 2.67M | -41.30% |
Total equity | 4.24M | — |
Shares outstanding | 5.82M | — |
Price to book | 1.56 | — |
Return on assets | -56.34% | — |
Return on capital | -75.16% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | -1.92M | -21.26% |
Cash from operations | -2.95M | -408.45% |
Cash from investing | — | — |
Cash from financing | -174.00K | 64.63% |
Net change in cash | -3.12M | -191.32% |
Free cash flow | -2.31M | -366.84% |
About
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis Wikipedia
Founded
2000
Headquarters
Website
Employees
14
